10 August 2017
PGA’s Anti-Doping Program Revised
The PGA TOUR has revised its Anti-Doping Program. The revisions, approved by the PGA Tour Policy Board, include the implementation of blood testing, supplementation of the Tour’s Prohibited List to include all of the substances and methods currently on the World Anti-Doping Agency (WADA) Prohibited List of Substances and Methods, and the reporting of suspensions related to drug abuse (recreational drugs).
The Tour will begin a comprehensive education program to ensure that all players understand the changes to the testing procedures, the Prohibited List, and the adjudication process in advance of the 2017-18 season.
“While we are extremely pleased with the implementation and results of the PGA Tour Anti-Doping Program to date, we believe that these changes to our program are prudent in that they further our objectives of protecting the well-being of our members and better substantiate the integrity of golf as a clean sport,” said PGA Tour Commissioner Jay Monahan in their release statement.
The revisions will take effect at the start of the 2017-18 PGA Tour Season. The PGA Tour Anti-Doping Program was first established in 2008 after discussions with many of the world’s foremost authorities in the anti-doping field, including representatives from WADA and the United States Anti-Doping Agency (USADA).